|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000038242 |
|
Date of registration:
|
09/10/2019 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
The effect of Evolocumab on primary nephrotic syndrome
|
|
Scientific title:
|
The effect of Evolocumab on primary nephrotic syndrome - The effect of Evolocumab on primary nephrotic syndrome |
|
Date of first enrolment:
|
2019/10/01 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043592 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Risa
Asai |
|
Address:
|
1-7-1 Nagayama, Tama-shi, Tokyo
Japan |
|
Telephone:
|
042-371-2111 |
|
Email:
|
rasai@nms.ac.jp |
|
Affiliation:
|
Nippon Medical School Tamanagayama Hospital Department of Nephrology |
|
|
Name:
|
Risa
Asai |
|
Address:
|
1-7-1 Nagayama, Tama-shi, Tokyo
206-8512
Japan |
|
Telephone:
|
042-371-2111 |
|
Email:
|
rasai@nms.ac.jp |
|
Affiliation:
|
Department of Nephrology, Nippon Medical School Department of Nephrology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1) Pregnant women 2) Secondary nephrotic syndrome 3) Clearly nephrotoxic treatment is undergoing 4) Patient judged inappropriate by the examining physician
Age minimum:
16years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Primary nephrotic syndrome
|
|
Intervention(s)
|
|
Evolocumab
|
|
Primary Outcome(s)
|
|
Remission rate
|
|
Secondary Outcome(s)
|
|
Remission introduction period, cumulative dose of prednisolone and immunosuppressant agents, reduction of the degree of proteinuria, change of serum albumin, adverse complication derived from prednisolone and immunosuppressant agents use, changes in the renal function
|
|
Source(s) of Monetary Support
|
|
Department of Nephrology, Nippon Medical School
|
|
Ethics review
|
Status: YES
Approval date: 01/10/2019
Contact:
rasai@nms.ac.jp
Nippon Medical School Tamanagayama Hospital
042-371-2111
rasai@nms.ac.jp
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
30/06/2024 |
|
URL:
|
|
|
|